20 March 2019
Public procurement in Catalonia has to overcome various challenges, such as the end goal for medicines, technology and, in general, new healthcare solutions in hospitals. The CataloniaBio & HealthTech Innovation Workgroup brought together six experts from companies, hospitals and legal services for the Hospital Connection event And how do you buy? on 22 February in Barcelona to debate the current framework and how it is expected to change.
New models for the relationship between businesses (supplier) and hospitals (purchaser) must be developed and the imbalance between large corporations and hospitals is a barrier to negotiations, agreed Ferran Rodríguez, head ...
13 March 2019
Interview to Jaume Amat, president of CataloniaBio & HealthTech since 2018 and CEO of Specipig:
It has been one year since the merger of CataloniaBio and the HealthTech Cluster. How would the board take stock of the past year?
When we started this new era, we believed that the merger addressed a trend and a real need in the sector resulting from the transversal nature of new healthcare solutions. One year later, we’re more sure of this than ever. As an association, we are much more diverse and, therefore, much richer and with more complimentary assets. We can be proud ...
13 March 2019
Banco Sabadell's BStartup has granted more than 200 million euros of funding to startups. The entity has been supporting emerging companies for more than five years, which has led to 2,895 startups becoming customers of the bank. Furthermore, through its investment vehicles BStartup10, Sabadell Venture Capital and InnoCells, the entity now holds a direct stake in 67 companies.
Further proof of Banco Sabadell’s commitment to the entrepreneurial ecosystem is the presence as a gold partner of 4 Years From Now (4YFN) organised by the Mobile World Congress in Barcelona and gold sponsor, for the fifth consecutive year, of the ...
12 March 2019
Montserrat Vendrell has been named the new president of the Pompeu Fabra University Board of Trustees (UPF), taking over from Núria Basi, who had held the position since 2008. The board is the body through which society participates in the UPF.
Vendrell is a partner in the venture capital fund Alta Life Sciences, member of the CataloniaBio & HealthTech board of directors and president of the executive committee at the Pasqual Maragall Foundation.
She is the third woman in a row to hold the position of president of the UPF Board of Trustees.
12 March 2019
Enantia, CataloniaBio & HealthTech member, has again succeeded in applying cocrystallisation technology to a new family of compounds, the cannabinoids.
Cannabinoids, especially cannabidiol (CBD) and tetrahydrocannabinol (THC), plays an important role in a number of biochemical pathways. Besides Sativex® and Epidiolex®, the only two approved drugs containing CBD, the potential of cannabinoids to be used to treat a large number of medical conditions is very high as is shown by the number of ongoing clinical trials.
Enantia has developed new cannabinoid cocrystals to allow their purification from complex mixtures (natural and synthetic) and to obtain improved active pharmaceutical ingredients and ...
12 March 2019
FreeOx Biotech has taken on AEC Partners as a strategic partner in the company to accelerate development and marketing of its drug to treat brain ischemia. Both companies are members of CataloniaBio & HealthTech.
The priority drug is Ox-01, which is about to begin phase-III clinical trials. AEC Partners analysed the brand positioning, financial needs and expected return. At the same time, negotiations are already under way with potential licensees in various world markets.
Jordi Esclusa, managing partner at AEC Partners, and Nerea Alonso, partner in the Barcelona offices of AEC Partners, explain that “It is highly satisfying to lead ...
8 March 2019
CataloniaBio & HealthTech has given the Biosuccess Award to the Ysios Capital fund for the milestones achieved in 2018 in the healthcare and biomedicine arena in Catalonia, and an honorary award to Antonio Parente recognising his career in business. The awards ceremony was held yesterday at the CataloniaBio & HealthTech Gala Dinner at the Sant Pau Art Nouveau Site in Barcelona and attended by Catalan Minister of Health Alba Vergés and more than 200 entrepreneurs, executives and investors in the sector.
The panel of judges valued Ysios' investment in the main operations in the sector in 2018 (STAT-Dx ...
21 February 2019
CataloniaBio & HealthTech held its ordinary general assembly on the 15 February at the Barcelona Science Park, where the members of the board, the executive team and around 70 members met to share and approve the 2019 action plan, as well as the management report and accounts from financial year 2018. The admission of 24 new partners* was also approved.
On behalf of the board, and in accordance with the bylaws, the participants included Jaume Amat (president), Maribel Bergés (treasurer), Àngel Alonso (secretary) and Melqui Calzado (secretary general of the association).
20 February 2019
Aromics, CataloniaBio & HealthTech member, has been awarded with 1,085.659 euros from the European Union for the regulatory preclinics of NAX035 for the treatment of malignant mesothelioma, an aggressive and highly refractory tumor directly related to asbestos exposure.
The financing of Aromics comes through the SME instrument Phase 2 of the Horizon 2020 program, which allows European companies to develop innovative products and services.
The use of asbestos will be definitively banned in the European Union in 2005 but it is a tumour with a long latency period (30 to 40 years from the exposure to the diagnosis ...
19 February 2019
Amgen Iberia, the subsidiary of biotechnology multinational corporation Amgen and a member of CataloniaBio & HealthTech, increased its staff by 11% in 2018, for a total of 300 employees, after launching a new biosimilars unit, according to L’Econòmic. The company notes that these employees are highly qualified and that they promote equal pay for women and men.
Amgen first began working in Spain in 1990. Currently, the company has nearly 80 clinical trials under way in its various therapeutic areas and invests €18 million in R&D. Its drugs are used to treat serious diseases in cardiology, nephrology, oncohaematology and bone ...